title: Efficacy of Lamivudine in patients with hematologic malignancies receiving chemotherapy and precore mutant chronic active hepatitis B.
authors.affiliation: First Department of Internal Medicine, School of Medicine, Democritus University of Thrace, Alexandroupolis, Greece.
authors.forename: Konstantinos
authors.initials: K
authors.lastname: Mimidis
authors.forename: Costas
authors.initials: C
authors.lastname: Tsatalas
authors.forename: Dimitris
authors.initials: D
authors.lastname: Margaritis
authors.forename: George
authors.initials: G
authors.lastname: Martinis
authors.forename: Emanuel
authors.initials: E
authors.lastname: Spanoudakis
authors.forename: Stamatia
authors.initials: S
authors.lastname: Kotsiou
authors.forename: George
authors.initials: G
authors.lastname: Kartalis
authors.forename: George
authors.initials: G
authors.lastname: Bourikas
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D004279:DNA, Viral / Q000097:blood; D005188:False Negative Reactions; D005260:Female; D019337:Hematologic Neoplasms / Q000150:complications* / Q000188:drug therapy; D006513:Hepatitis B e Antigens / Q000097:blood / Q000235:genetics; D019694:Hepatitis B, Chronic / Q000175:diagnosis / Q000188:drug therapy / Q000517:prevention & control*; D006801:Humans; D019259:Lamivudine / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D008297:Male; D008875:Middle Aged; D009154:Mutation; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D013810:Therapeutic Equivalency
chemical_list: D004279:DNA, Viral; D006513:Hepatitis B e Antigens; D018894:Reverse Transcriptase Inhibitors; D019259:Lamivudine